- Home
- FTHM vs GDTC Comparison
FTHM vs GDTC Comparison
Compare FTHM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- GDTC
- Stock Information
- Founded
- FTHM 2010
- GDTC 2018
- Country
- FTHM United States
- GDTC Singapore
- Employees
- FTHM N/A
- GDTC N/A
- Industry
- FTHM Real Estate
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- GDTC Health Care
- Exchange
- FTHM Nasdaq
- GDTC Nasdaq
- Market Cap
- FTHM 33.6M
- GDTC 28.0M
- IPO Year
- FTHM 2020
- GDTC 2023
- Fundamental
- Price
- FTHM $1.41
- GDTC $2.08
- Analyst Decision
- FTHM Buy
- GDTC Buy
- Analyst Count
- FTHM 1
- GDTC 1
- Target Price
- FTHM $2.50
- GDTC $5.00
- AVG Volume (30 Days)
- FTHM 75.3K
- GDTC 5.7K
- Earning Date
- FTHM 08-11-2025
- GDTC 01-01-0001
- Dividend Yield
- FTHM N/A
- GDTC N/A
- EPS Growth
- FTHM N/A
- GDTC N/A
- EPS
- FTHM N/A
- GDTC N/A
- Revenue
- FTHM $357,816,000.00
- GDTC $368,838.00
- Revenue This Year
- FTHM $32.40
- GDTC $5.37
- Revenue Next Year
- FTHM $18.04
- GDTC N/A
- P/E Ratio
- FTHM N/A
- GDTC N/A
- Revenue Growth
- FTHM 5.80
- GDTC N/A
- 52 Week Low
- FTHM $0.65
- GDTC $1.20
- 52 Week High
- FTHM $3.37
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- FTHM 65.20
- GDTC 48.83
- Support Level
- FTHM $1.24
- GDTC $2.07
- Resistance Level
- FTHM $1.36
- GDTC $2.34
- Average True Range (ATR)
- FTHM 0.09
- GDTC 0.09
- MACD
- FTHM 0.03
- GDTC 0.00
- Stochastic Oscillator
- FTHM 88.46
- GDTC 50.97
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.